Descripción de la empresa
EUDA Health Holdings Limited operates as a provider of non-invasive healthcare services with a primary geographic footprint in Singapore, Malaysia, and China, offering specialized treatments such as bioenergy capsules, stem cell therapy, and CRISPR gene editing alongside supplement sales and property management. The enterprise functions within the Real Estate sector, specifically classified under Real Estate Services, which suggests a business model that may leverage asset management or service-based revenue streams rather than traditional property ownership. In terms of scale, the company holds a market capitalization of $13.40M and generates $5.16M in annual revenue while employing 117 individuals. These valuation figures indicate that EUDA Health is a micro-cap entity with a relatively modest revenue base compared to large-cap peers, reflecting a niche operational scope where growth potential is currently being driven by significant percentage increases rather than massive absolute revenue volumes.
Salud financiera
The company reported total revenue of $5.16M over the trailing twelve months, yet it recorded a net income loss of $2,064,341 and an EBITDA of $-1,992,526, revealing a substantial gap between top-line generation and bottom-line profitability that points to a high-cost structure or significant operational expenses. This negative free cash flow of $3,350,164 indicates that the company's operating activities are consuming cash reserves faster than they are generating them, which limits immediate financial flexibility for capital expenditures or debt repayment. Profitability metrics present a complex picture with a gross margin of 22.4%, contrasting sharply against an operating margin of -37.0% and a profit margin of 5.2%, suggesting that while the core service delivery retains value, overhead costs and administrative expenses are eroding operational efficiency significantly. The balance sheet shows a cash balance of $176,584 against total debt of $2.28M, a disparity that highlights a leveraged position given the N/A debt-to-equity ratio, implying the firm relies heavily on external financing relative to its equity base. Liquidity is constrained further by a current ratio of 0.23, which signifies that current assets are less than one-third of current liabilities, indicating a potential inability to meet short-term obligations without refinancing or asset sales. Return on Equity is listed as N/A due to the negative equity position, while the return on assets stands at -63.9%, demonstrating that the management team is currently destroying value per unit of asset deployed rather than generating a positive return.
Evaluación de valoración
The trailing twelve-month P/E ratio is 17.73, whereas the forward P/E is significantly lower at 4.43, implying that the market expects earnings to turn positive or improve drastically in the future to justify the current multiple, despite the current unprofitability. The price-to-book ratio is -3.55, a negative figure that indicates the market prices the company below its book value, reflecting investor concerns about the sustainability of its assets and liabilities rather than a premium valuation. Alternative valuation metrics such as the price-to-sales ratio of 2.60 and an EV/EBITDA of -7.66 suggest that traditional earnings-based comparisons are less relevant, forcing reliance on revenue multiples or enterprise value measures that account for the negative earnings environment. The stock has exhibited significant price volatility over the last year, trading between a 52-week low of $6.42 and a high of $86.00, meaning the current price is positioned far below the 52-week high, reflecting a substantial correction from peak levels. The beta of 0.16 indicates that the stock's price movements are much less volatile than the broader market, suggesting it may offer a lower risk profile in terms of correlation to market swings, although this must be weighed against the fundamental financial distress signals present in the financial health section.
Growth & Income
Revenue growth for the year-over-year period stands at 60.2%, while earnings growth is listed as N/A due to the company's unprofitable status, implying that top-line expansion is currently the primary driver of company development rather than profitability scaling. Since the company does not pay dividends, indicated by a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are theoretically retained to fund operations or future growth initiatives rather than being distributed to shareholders. The overall growth and income profile is characterized by aggressive revenue expansion coupled with a complete absence of dividend income, requiring investors to rely entirely on potential capital appreciation or a future turnaround in profitability for total return. This profile suggests a high-risk, high-reward dynamic where the 60.2% revenue surge must eventually translate into operational efficiency to support the negative operating margins and free cash flow observed in recent periods.